Systemic lupus erythematosus (SLE) is a severe chronic inflammatory autoimmune disease that may affect different organs of the body. Biotest is developing innovative therapeutic strategies with the objective of effectively but gently decelerating the overactive immune system in SLE. The focus is on the monoclonal antibody BT-063 Based on the current preclinical data, it neutralizes an immune messenger molecule, which plays a significant role in SLE. This - it is hoped - will reduce the symptoms of patients suffering from the disease.